logo-loader
RNS
ConvaTec Group PLC

ConvaTec Group PLC - Result of AGM

RNS Number : 5704Y
ConvaTec Group PLC
09 May 2019
 

 

 

         ConvaTec Group Plc

 

Results of Annual General Meeting

 

 

Reading, United Kingdom 9 May 2019 - Poll Result

 

ConvaTec Group Plc ("ConvaTec"), a leading global medical products and technologies company, held its annual general meeting today. The results of the poll held in relation to the resolutions proposed at the meeting are set out below.

 

Resolution

Votes

For

%

Votes Against

%

 

Votes Total

% of ISC Voted

Votes Withheld

1. Receive Annual Reports and Accounts

1,575,538,540

100.00

2,829

0.00

1,575,541,369

80.13%

 

543,903

2. Approve the Directors' Remuneration Report

969,813,968

61.55

605,893,489

38.45

1,575,707,457

80.14%

377,814

3. Approve Final Dividend

1,576,084,188

100.00

0

0.00

1,576,084,188

80.16%

1,084

4. Re-elect Rick Anderson as a director

1,573,217,469

99.83

2,728,480

0.17

1,575,945,949

80.15%

139,323

5. Re-elect Frank Schulkes as a director

1,572,958,293

99.81

2,987,656

0.19

1,575,945,949

80.15%

139,323

6. Re-elect Jesper Ovesen as a director

1,449,805,632

92.00

126,138,817

8.00

1,575,944,449

80.15%

140,823

7. Re-elect Ros Rivaz as a director

1,438,203,922

91.28

137,371,231

8.72

1,575,575,153

80.13%

510,119

8. Re-elect Regina Benjamin as a director

1,574,381,440

99.90

1,564,509

0.10

1,575,945,949

80.15%

139,323

9. Re-elect Margaret Ewing as a director

1,574,012,144

99.88

1,933,805

0.12

1,575,945,949

80.15%

139,323

10. Elect Sten Scheibye as a director

1,573,315,958

99.83

2,628,491

0.17

1,575,944,449

80.15%

140,823

11. Re-appoint Deloitte LLP as auditors

1,576,075,654

100.00

7,835

0.00

1,576,083,489

80.16%

1,783

12. Authorise the Directors to agree the auditors' remuneration

1,575,937,624

100.00

7,835

0.00

1,575,945,459

80.15%

139,813

13. Authorise allotment of shares

1,547,503,417

98.34

26,073,883

1.66

1,573,577,300

80.03%

2,507,972

14. Renew the Scrip Dividend Scheme.

1,553,044,306

98.56

22,671,144

1.44

1,575,715,450

80.14%

369,822

15. Disapply pre-emption rights*

1,537,679,127

97.59

38,030,923

2.41

1,575,710,050

80.14%

375,222

16. Disapply pre-emption rights in connection with an acquisition or specified capital investment*

1,485,134,202

94.37

88,580,827

5.63

1,573,715,029

80.04%

2,370,242

17. Authorise purchase of own shares*

1,575,202,274

99.97

524,653

0.03

1,575,726,927

80.14%

358,344

18. Authorise political donations and political expenditure

1,552,199,261

98.77

19,375,261

1.23

1,571,574,522

79.93%

4,510,750

19. Call general meetings on 14 days' notice*

1,529,148,452

97.30

42,426,837

2.70

1,571,575,289

79.93%

 

 

 

4,509,983

 

*Special Resolution

 

NOTES:

1.   All resolutions were passed.

2.   Votes "For" and "Against" are expressed as a percentage of votes received.

3.   A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

4.   Total number of shares in issue at close of business on 8 May 2019 was 1,966,155,724 shares.  80.16% of capital was voted.

5.   Computershare acted as scrutineer of the poll on all resolutions.

 

In accordance with Listing Rule 9.6.2, copies of the resolutions that do not constitute ordinary business that were passed at the annual general meeting have been submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/NSM.

 

 

AGM - Resolution Two

 

The Board of ConvaTec is pleased to have received shareholder approval for all resolutions proposed at the AGM today. Naturally, the Board is disappointed with the lower level of support for the Directors' Remuneration Report for the year ending 31 December 2018. 38.45% shareholders voted against the resolution to approve the Remuneration Report, 61.55% voted in favour and 377,814 votes abstained. We have engaged in a dialogue with a number of shareholders and proxy advisors to discuss their questions and concerns.

 

In line with the Companies Act, ConvaTec will put a new Remuneration Policy to shareholders at the Company's next AGM, in May 2020. The new Policy will be designed under our new Remuneration Committee Chair, and ConvaTec will undertake a comprehensive consultation with shareholders to ensure that their views are understood and taken into consideration by the Remuneration Committee in its review of, and any proposed amendments to, the current Remuneration Policy.

 

 

Committee Changes

 

The Company is pleased to announce that Margaret Ewing, Non-Executive Director has been appointed Chair of the Nomination Committee and member of the Remuneration Committee, effective immediately. Rick Anderson, Executive Chairman, has been appointed Chair of the Corporate Responsibility Committee and member of the Nomination Committee, effective immediately. These changes follow the retirement of Sir Christopher Gent, at the AGM earlier today and as previously announced on 25 March 2019. This statement is made in accordance with Listing Rule 9.6.11.

 

 

About ConvaTec

 

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

 

 

 

Enquiries

 

Analysts and Investors

 

John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435

Mark Reynolds, Director Investor Relations, ConvaTec                 +44 (0) 7551 036 625

investorrelations@convatec.com

 

Media

 

Bobby Leach, VP Group Corporate Affairs, ConvaTec                   +44 (0)7770 842 226

Alastair Elwen, Finsbury                                                                  +44 (0)207 251 3801
 

LEI:   213800LS272L4FIDOH92

# # #

END


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGUKUVRKRAVRAR
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read